- Home
- GF vs ARCT Comparison
GF vs ARCT Comparison
Compare GF & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GF | ARCT |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.1M | 369.5M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GF | ARCT |
|---|---|---|
| Price | $10.26 | $12.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $23.80 |
| AVG Volume (30 Days) | 25.5K | ★ 756.6K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.98 | $5.50 |
| 52 Week High | $12.49 | $24.14 |
Technical Indicators
Market Signals| Indicator | GF | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 42.66 |
| Support Level | $9.98 | $6.53 |
| Resistance Level | $12.38 | $17.85 |
| Average True Range (ATR) | 0.19 | 1.11 |
| MACD | -0.02 | -0.31 |
| Stochastic Oscillator | 6.63 | 8.31 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.